Kevin McCulloch was named President and Chief Operating Officer of Xeris in August 2024. He joined Xeris Pharmaceuticals in October 2018 as Senior Vice President, Global Operations and Business Development and was named Chief Commercial Officer in September 2021. Mr. McCulloch has spent more than 35 years in the pharmaceutical and medical device industry in diverse leadership and general management roles spanning sales, marketing, and business operations for both US and international entities.
Prior to joining Xeris, Kevin was the President of Global Solutions at Hill-Rom and earlier, as Chief Business Officer for Water Street Healthcare Partners Pharmaceutical Holdings. Mr. McCulloch spent 15 years with Baxter Healthcare in successive management roles including GM/President of the Global Services, Global Fluid Systems (GFS), Infusion Systems (IS), and Fenwal business units. While the leader of GFS, he created Celerity Pharmaceuticals, one of the industry’s first R&D externalization ventures that has since successfully generated multiple new product launches. As leader of the IS business, he oversaw the acquisition and integration of Sigma International into the IS portfolio while successfully navigating the business out of a long-standing consent decree. As the President of Fenwal, a global leader in blood collection and apheresis technology, Mr. McCulloch led its successful divestiture to TPG in 2007. He started his Baxter career as a Vice President of Global Marketing in the Renal division. Prior to Baxter, Mr. McCulloch spent 9 years at GD Searle in roles of increasing responsibility in business development, marketing, and sales. He began his career as a territory sales representative with the Upjohn Company.
Mr. McCulloch holds an MBA from Northwestern University’s Kellogg School of Management and a BS in Biology from the University of Michigan.
What is Kevin McCulloch's net worth?
The estimated net worth of Kevin McCulloch is at least $11.48 million as of June 13th, 2025. Mr. McCulloch owns 1,708,585 shares of Xeris Biopharma stock worth more than $11,481,691 as of December 5th. This net worth approximation does not reflect any other investments that Mr. McCulloch may own. Learn More about Kevin McCulloch's net worth.
How do I contact Kevin McCulloch?
Has Kevin McCulloch been buying or selling shares of Xeris Biopharma?
Kevin McCulloch has not been actively trading shares of Xeris Biopharma within the last three months. Most recently, on Friday, June 13th, Kevin Mcculloch bought 25,000 shares of Xeris Biopharma stock. The stock was acquired at an average cost of $4.38 per share, with a total value of $109,500.00. Following the completion of the transaction, the insider now directly owns 1,708,585 shares of the company's stock, valued at $7,483,602.30. Learn More on Kevin McCulloch's trading history.
Who are Xeris Biopharma's active insiders?
Are insiders buying or selling shares of Xeris Biopharma?
In the last year, Xeris Biopharma insiders bought shares 1 times. They purchased a total of 25,000 shares worth more than $109,500.00. In the last year, insiders at the sold shares 8 times. They sold a total of 304,308 shares worth more than $2,181,194.23. The most recent insider tranaction occured on December, 1st when insider Beth Hecht sold 16,667 shares worth more than $116,835.67. Insiders at Xeris Biopharma own 6.5% of the company.
Learn More about insider trades at Xeris Biopharma. Information on this page was last updated on 12/1/2025.
